A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: * Subject must be 18 years of age or older at the time the Informed Consent is signed. * The subject (or legally acceptable representative if applicable) must provide written informed consent for the trial. * Pathologic diagnosis of prostate cancer of adenocarcinoma or small cell histology. * Metastatic disease as documented by technetium-99m (99mTc) bone scan or metastatic lesions by computed tomography (CT) or magnetic resonance imaging (MRI) scans (visceral or lymph node disease). CT-portion of FDG-PET/CT or scan may be used for eligibility. NaF PET-CT is an alternative to 99mTc bone scan. If lymph node metastasis is the only evidence of metastatic disease, it must be 1.5 cm in short axis and above the level of the iliac bifurcation. Imaging studies for the purpose of determining eligibility must be completed within 60 days of Day 1. * Progressive castration resistant prostate cancer as defined by serum testosterone \< 50 ng/mL and one of the following: * PSA…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source